Sinopharm Group (OTCMKTS:SHTDF – Get Free Report) is anticipated to announce its results before the market opens on Wednesday, March 18th. Analysts expect the company to announce earnings of $0.1630 per share and revenue of $40.5328 billion for the quarter.
Sinopharm Group Price Performance
SHTDF stock opened at $2.63 on Thursday. The business has a fifty day moving average price of $2.49 and a 200 day moving average price of $2.46. Sinopharm Group has a fifty-two week low of $2.11 and a fifty-two week high of $2.70.
Sinopharm Group Company Profile
Sinopharm Group Co, Ltd is one of China’s largest state-owned integrated healthcare companies, primarily focused on the research, development, production and distribution of a broad range of pharmaceutical and healthcare products. Established in 1998 through the reorganization of assets under China National Pharmaceutical Group (Sinopharm), the company has grown to encompass multiple business segments, including prescription medicines, over-the-counter drugs, vaccines and medical devices. Sinopharm Group is listed on the Hong Kong Stock Exchange and trades in the United States through its OTCMKTS ticker SHTDF.
The company’s product portfolio spans chemically synthesized drugs, biologics and traditional Chinese medicine formulations, supported by an extensive nationwide manufacturing and quality-control network.
Featured Stories
- Five stocks we like better than Sinopharm Group
- The Next Commodity Crunch (bigger than oil?)
- What a Former CIA Agent Knows About the Coming Collapse
- I tried out Elon Musk’s new AI tech — it floored me
- “I just bought 10,000 shares of a $5 stock…”
- Nvidia CEO Issues Bold Tesla Call
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
